Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.50 |
| ▸ | ARG2 | P78540 | 1/20 | 0.50 |
| ▸ | GGT1 | P19440 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 5/20 | 0.33 |
| ▸ | NOS1 | P29475 | 3/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20978268 | 1.00 | ARG1 (0.50) | ARG1ARG2GGT1KDM4CNOS2 | |
| SCHEMBL1455221 | 1.00 | ARG1 (0.50) | ARG1ARG2GGT1KDM4CNOS2 | |
| SCHEMBL28429572 | 0.94 | ARG1 (0.53) | ARG1ARG2GGT1KDM4CNOS2 | |
| SCHEMBL31370370 | 0.94 | ARG1 (0.53) | ARG1ARG2GGT1KDM4CNOS2 | |
| SCHEMBL8844992 | 0.85 | ARG1 (0.47) | ARG1ARG2GGT1KDM4CNOS2 | |
| SCHEMBL6431682 | 0.85 | ARG1 (0.47) | ARG1ARG2GGT1KDM4CNOS2 | |
| SCHEMBL161929 | 0.85 | ARG1 (0.47) | ARG1ARG2GGT1KDM4CNOS2 | |
| SCHEMBL202490 | 0.85 | ARG1 (0.47) | ARG1ARG2GGT1KDM4CNOS2 | |
| Hydrochloric Acid SCHEMBL11674295 | 0.84 | ARG1 (0.46) | ARG1ARG2GGT1KDM4CNOS2 | |
| Hydrochloric Acid SCHEMBL11674300 | 0.84 | ARG1 (0.46) | ARG1ARG2GGT1KDM4CNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012106469-A2 | METHODS FOR TREATING INFECTIONS BY TARGETING MICROBIAL H2S-PRODUCING ENZYMES | NEW YORK UNIVERSITY (US) | 2012-08-09 | — | — | WO | claimed |
| US-20120172292-A1 | METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE | NEW YORK UNIVERSITY (US) | 2012-07-05 | — | — | US | claimed |
| WO-2011032000-A2 | METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE | NEW YORK UNIVERSITY (US) | 2011-03-17 | — | — | WO | claimed |
| CN-111479823-A | Peptide conjugate CGRP receptor antagonist and preparation method and application thereof | 奥克兰联合服务有限公司 | 2020-07-31 | — | — | CN | disclosed |
| US-20140066362-A1 | METHOD FOR TREATING INFECTIONS BY TARGETING MICROBIAL H2S-PRODUCING ENZYMES | NEW YORK UNIVERSITY (US) | 2014-03-06 | — | — | US | disclosed |
| US-20120172292-A1 | METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE | NEW YORK UNIVERSITY (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2011032000-A2 | METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE | NEW YORK UNIVERSITY (US) | 2011-03-17 | — | — | WO | disclosed |
| US-7345055-B2 | Substituted C-imidazo [1,2-α] pyridin-3-yl-methylamines | GRUENENTHAL GMBH (DE) | 2008-03-18 | — | — | US | disclosed |
| US-7342025-B2 | Substituted C-imidazo[1,2-a]pyridin-3-yl-methylamines | GRUENENTHAL GMBH (DE) | 2008-03-11 | — | — | US | disclosed |
| US-7320980-B2 | Substituted pyrido(1,2-a)pyrimidines and their use as NOS inhibitors | GRUENENTHAL GMBH (DE) | 2008-01-22 | — | — | US | disclosed |
| US-7271192-B2 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | GRUENENTHAL GMBH (DE) | 2007-09-18 | — | — | US | disclosed |
| US-20050014815-A1 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | GRUENENTHAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
| US-20040176394-A1 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | GRUNENTHAL GMBH (DE) | 2004-09-09 | — | — | US | disclosed |
| US-20040142961-A1 | Utilization of substituted imidazo[1,2-a]-pyridine compounds in pharmaceutical formulations | GRUENENTHAL GMBH (DE) | 2004-07-22 | — | — | US | disclosed |
| US-20040122044-A1 | Utilization of substituted imidazo [1,2-A]-pyridin-3-yl-amide and imidazo [1,2-A]-pyridin-3-yl-amine compounds in pharmaceutical formulations | GRUENENTHAL GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| US-6703404-B2 | NITRIC OXIDE SYNTHASE INHIBITORS | GRUENENTHAL GMBH (DE) | 2004-03-09 | — | — | US | disclosed |
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| CN-1407983-A | Tert-butyl-(7-methyl-imidazo [1,2-A] pyridine-3-yl)-amine derivatives | GRUENENTHAL GMBH (DE) | 2003-04-02 | — | — | CN | disclosed |
| US-20030022914-A1 | Tert.-butyl-(7-menthyl-imidazol [1,2-A] pyridin-3-yl)-amine derivatives | GRUENENTHAL GMBH . | 2003-01-30 | — | — | US | disclosed |
| WO-1996018405-A1 | PREVENTING CONVERSION OF CITRULLINE TO ARGININOSUCCINATE TO LIMIT PATHOLOGICAL NITRIC OXIDE OVERPRODUCTION | THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION, INC. (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014815-A1 | Substituted 2-pyrrolidine-2-yl-1H-indole compounds | IDO1, IDO2, TPH2 | ARG1 19/4885ARG2 6/4885GGT1 4358/4885 |
| US-20120172292-A1 | METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE | NOS2, NOS1, NOS3 | ARG1 30/4885ARG2 9/4885GGT1 123/4885 |
| US-20040142961-A1 | Utilization of substituted imidazo[1,2-a]-pyridine compounds in pharmaceutical formulations | QDPR, PTGIS, DPYD | ARG1 238/4885ARG2 119/4885GGT1 1577/4885 |
| US-20030022914-A1 | Tert.-butyl-(7-menthyl-imidazol [1,2-A] pyridin-3-yl)-amine derivatives | TERT, BET1, TRPM7 | ARG1 115/4885ARG2 312/4885GGT1 4233/4885 |
| US-20040176394-A1 | Use of substituted gamma-lactone compounds as pharmaceutical preparations | BACE1, MYC, APP | ARG1 2976/4885ARG2 2876/4885GGT1 1255/4885 |
| US-20040122044-A1 | Utilization of substituted imidazo [1,2-A]-pyridin-3-yl-amide and imidazo [1,2-A]-pyridin-3-yl-amine compounds in pharmaceutical formulations | NOS1, NAT1, NOS3 | ARG1 33/4885ARG2 56/4885GGT1 2046/4885 |
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | NOS1, PTGIS, NOS2 | ARG1 50/4885ARG2 102/4885GGT1 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.